



FOR IMMEDIATE RELEASE

CONTACT:

Pete Joiner
President/CEO, Madeira Therapeutics
913.661.1962
pjoiner@madeiratherapeutics.com

MEDIA:

Kelly Sladek
SCORR Marketing
308.237.5567
kelly@scormarketing.com

Madeira Therapeutics to Present at the 2010 BIO International Convention

(LEAWOOD, KS; April 27, 2010) – [Madeira Therapeutics](#), a Kansas-based company specializing in [pediatric pharmaceuticals](#), announced today that Pete Joiner, Madeira president and chief executive officer, will present at the annual [BIO International Convention](#).

Joiner will present his topic, “Career Management: Transitioning Between Small and Large Pharma,” during the Career Management Program on May 4, 2010, from 10:45-11:30 am in the Biotech Now Lounge at the McCormick Place Convention Center in Chicago, Illinois. He will present alongside the following speakers and their companies: Scott M. Szczesny, PharmaLogics Recruiting; John Thottathil, an independent consultant (previously with New River Pharmaceuticals); Dong Wen, Upsher Smith Labs; Ravi Kiron, Adjuvant Global Advisors; and Ellen Derrico, Greater Philadelphia Senior Executive Group.

More than 185 companies working on innovations to heal, fuel and feed the world will present their research, insights to technology and overall accomplishments at the BIO International Convention. The convention is the largest global event for the biotechnology industry. Each year, BIO attracts the biggest names in biotech, offers key networking and partnering opportunities and provides insights and inspiration on the major trends affecting the industry.

“It is an honor to be able to present at the BIO International Convention on behalf of Madeira Therapeutics. Clearly, our core missions are aligned—with BIO focusing on fulfilling the promise of biotechnology and Madeira’s focus on delivering true pediatric formulations. The transition and usage of those technologies and science between large and small pharma corporations is a topic I am well versed in,” said Joiner. Visit Madeira Therapeutics at the Kansas pavilion, booth 4506.

Currently, Madeira Therapeutics has two pediatric products in development: MT-001, the first ever liquid preparation of a cholesterol-lowering statin for children and the elderly, and MT-003, a liquid preparation of an analgesic for the treatment of acute pain.

About Madeira Therapeutics

Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals who serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA's 505(b)(2) approval method, which relies in part on the regulatory agency's findings for a drug previously approved for adults, thereby shortcutting IND approval by years and saving tens of millions of dollars in development costs. The company's lead program, MT-001, is the first ever liquid preparation of a statin developed for the geriatric and pediatric population. The company's second product is MT-003 for acute pain relief. For more information, please visit www.madeiratherapeutics.com.

###